Browse ELF5

Summary
SymbolELF5
NameE74-like factor 5 (ets domain transcription factor)
Aliases ESE2; epithelium-restricted ESE-1-related Ets factor; epithelium-specific Ets transcription factor 2; ESE-2; ......
Chromosomal Location11p13-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus
Domain PF00178 Ets-domain
PF02198 Sterile alpha motif (SAM)/Pointed domain
Function

Transcriptionally activator that may play a role in regulating the later stages of keratinocytes terminal differentiation. ; FUNCTION: Isoform 2 binds to DNA sequences containing the consensus nucleotide core sequence GGA[AT]. Transcriptionally activates SPRR2A and the parotid gland-specific PSP promoters.

> Gene Ontology
 
Biological Process GO:0001704 formation of primary germ layer
GO:0001705 ectoderm formation
GO:0001712 ectodermal cell fate commitment
GO:0007369 gastrulation
GO:0007398 ectoderm development
GO:0010668 ectodermal cell differentiation
GO:0019827 stem cell population maintenance
GO:0030879 mammary gland development
GO:0035019 somatic stem cell population maintenance
GO:0045165 cell fate commitment
GO:0048732 gland development
GO:0060644 mammary gland epithelial cell differentiation
GO:0060795 cell fate commitment involved in formation of primary germ layer
GO:0061180 mammary gland epithelium development
GO:0098727 maintenance of cell number
Molecular Function GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04917 Prolactin signaling pathway
Reactome -
Summary
SymbolELF5
NameE74-like factor 5 (ets domain transcription factor)
Aliases ESE2; epithelium-restricted ESE-1-related Ets factor; epithelium-specific Ets transcription factor 2; ESE-2; ......
Chromosomal Location11p13-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ELF5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between ELF5 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26717410Luminal A Breast CarcinomaPromote immunity (infiltration)In the mouse mammary tumor virus-Polyoma Middle T (MMTV-PyMT) model of luminal breast cancer, induction of ELF5 levels increased leukocyte infiltration, angiogenesis, and blood vessel permeability in primary tumors and greatly increased the size and number of lung metastasis.
Summary
SymbolELF5
NameE74-like factor 5 (ets domain transcription factor)
Aliases ESE2; epithelium-restricted ESE-1-related Ets factor; epithelium-specific Ets transcription factor 2; ESE-2; ......
Chromosomal Location11p13-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ELF5 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolELF5
NameE74-like factor 5 (ets domain transcription factor)
Aliases ESE2; epithelium-restricted ESE-1-related Ets factor; epithelium-specific Ets transcription factor 2; ESE-2; ......
Chromosomal Location11p13-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ELF5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2090.484
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3540.541
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.6250.219
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2410.698
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.8630.521
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5340.708
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.4610.588
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.3960.823
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.6950.696
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0820.835
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0820.892
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.7170.0376
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ELF5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.305.30.507
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolELF5
NameE74-like factor 5 (ets domain transcription factor)
Aliases ESE2; epithelium-restricted ESE-1-related Ets factor; epithelium-specific Ets transcription factor 2; ESE-2; ......
Chromosomal Location11p13-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ELF5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolELF5
NameE74-like factor 5 (ets domain transcription factor)
Aliases ESE2; epithelium-restricted ESE-1-related Ets factor; epithelium-specific Ets transcription factor 2; ESE-2; ......
Chromosomal Location11p13-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ELF5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ELF5.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolELF5
NameE74-like factor 5 (ets domain transcription factor)
Aliases ESE2; epithelium-restricted ESE-1-related Ets factor; epithelium-specific Ets transcription factor 2; ESE-2; ......
Chromosomal Location11p13-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ELF5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolELF5
NameE74-like factor 5 (ets domain transcription factor)
Aliases ESE2; epithelium-restricted ESE-1-related Ets factor; epithelium-specific Ets transcription factor 2; ESE-2; ......
Chromosomal Location11p13-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ELF5 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolELF5
NameE74-like factor 5 (ets domain transcription factor)
Aliases ESE2; epithelium-restricted ESE-1-related Ets factor; epithelium-specific Ets transcription factor 2; ESE-2; ......
Chromosomal Location11p13-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ELF5 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolELF5
NameE74-like factor 5 (ets domain transcription factor)
Aliases ESE2; epithelium-restricted ESE-1-related Ets factor; epithelium-specific Ets transcription factor 2; ESE-2; ......
Chromosomal Location11p13-p12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ELF5 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.